TY - JOUR
T1 - A phase I study of flavopiridol in combination with gemcitabine and irinotecan in patients with metastatic cancer
AU - Fekrazad, Houman M.
AU - Verschraegen, Claire F.
AU - Royce, Melanie
AU - Smith, Harriet O.
AU - Lee, Fa Chyi
AU - Rabinowitz, Ian
PY - 2010/8
Y1 - 2010/8
N2 - Background: Flavopiridol (HMR 1275) is a synthetic flavone with antineoplastic properties through inhibition of cyclin-dependent kinase inhibitor. Flavopiridol synergizes in a sequence-dependent fashion with chemotherapy. Major adverse events of flavopiridol in single agent phase I studies are secretory diarrhea, neutropenia, thrombosis, and fatigue. Patients and Methods: Patients with advanced solid tumors were treated with gemcitabine 800 mg/m2 and irinotecan 80 mg/m2 on day 1, followed by flavopiridol, starting dose of 30 mg/m2 on day 2 with increment of 15 mg/m2 per dose level, repeated on days 8 and 9 for the first 6 patients (3-week cycle), and then repeated on days 15 and 16 for the remainder patients (4-week cycle). The protocol had to be amended for inability to redose after 1 week. Results: Fourteen women and 7 men with advanced solid tumors were enrolled. The median age was 51 years and the median number of prior chemotherapies was 3 (0-9). Neutropenic sepsis (1 patient), grade 3 diarrhea (1 patient), and neutropenia (2 patients) preventing retreatment on day 8 were observed among the 6 subjects treated on the first schedule. The recommended phase II dose of flavopiridol was 45 mg/m2 in combination with irinotecan and gemcitabine every 2 weeks. Dose-limiting toxicities were electrolyte imbalance with fatigue (1 patient), and renal failure and dyspnea with hypoxia (1 patient each), seen at 45 and 60 mg/m2 doses, respectively. The most common side effects were fatigue (81%), nausea (71%), diarrhea (67%), transient myelosuppression (43%), and vomiting (24%). Conclusions: The every 2 week dosing is well tolerated with a phase II recommended dose of 45 mg/m2 of flavopiridol in combination with irinotecan (80 mg/m2) and gemcitabine (800 mg/m2).
AB - Background: Flavopiridol (HMR 1275) is a synthetic flavone with antineoplastic properties through inhibition of cyclin-dependent kinase inhibitor. Flavopiridol synergizes in a sequence-dependent fashion with chemotherapy. Major adverse events of flavopiridol in single agent phase I studies are secretory diarrhea, neutropenia, thrombosis, and fatigue. Patients and Methods: Patients with advanced solid tumors were treated with gemcitabine 800 mg/m2 and irinotecan 80 mg/m2 on day 1, followed by flavopiridol, starting dose of 30 mg/m2 on day 2 with increment of 15 mg/m2 per dose level, repeated on days 8 and 9 for the first 6 patients (3-week cycle), and then repeated on days 15 and 16 for the remainder patients (4-week cycle). The protocol had to be amended for inability to redose after 1 week. Results: Fourteen women and 7 men with advanced solid tumors were enrolled. The median age was 51 years and the median number of prior chemotherapies was 3 (0-9). Neutropenic sepsis (1 patient), grade 3 diarrhea (1 patient), and neutropenia (2 patients) preventing retreatment on day 8 were observed among the 6 subjects treated on the first schedule. The recommended phase II dose of flavopiridol was 45 mg/m2 in combination with irinotecan and gemcitabine every 2 weeks. Dose-limiting toxicities were electrolyte imbalance with fatigue (1 patient), and renal failure and dyspnea with hypoxia (1 patient each), seen at 45 and 60 mg/m2 doses, respectively. The most common side effects were fatigue (81%), nausea (71%), diarrhea (67%), transient myelosuppression (43%), and vomiting (24%). Conclusions: The every 2 week dosing is well tolerated with a phase II recommended dose of 45 mg/m2 of flavopiridol in combination with irinotecan (80 mg/m2) and gemcitabine (800 mg/m2).
KW - Chemotherapy combination
KW - Cyclin-dependent kinase inhibitor
KW - Flavopiridol
KW - Phase I
UR - http://www.scopus.com/inward/record.url?scp=77956631074&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77956631074&partnerID=8YFLogxK
U2 - 10.1097/COC.0b013e3181b2043f
DO - 10.1097/COC.0b013e3181b2043f
M3 - Article
C2 - 19884803
AN - SCOPUS:77956631074
SN - 0277-3732
VL - 33
SP - 393
EP - 397
JO - American Journal of Clinical Oncology: Cancer Clinical Trials
JF - American Journal of Clinical Oncology: Cancer Clinical Trials
IS - 4
ER -